Bergen, Norway, 17 November 2017 - The Board of Directors in BerGenBio ASA's
(the "Company") (OSE: BGBIO) has, to fulfil the Company's obligations under the
option agreements, resolved to increase the Company's share capital by minimum
NOK 0,10 and maximum NOK 21,500 by issuance of minimum 1 and maximum 215,000 new
shares. The new shares shall be subscribed for by the employees that wish and
are entitled to exercise options in accordance with the Company's option scheme.
The subscription price shall be in accordance with the prevailing option price
pursuant to the Company´s option scheme, ie NOK 5.65 - NOK 16.01 per share. The
shares shall be subscribed for in a separate subscription document in the period
from 18. November 2017 and up to and including 30. November 2017.
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Tom Henrik Sundby
Finance Director, BerGenBio ASA
tom.sundby@bergenbio.com
+47 477 54 415
Forward looking statements
This announcement may contain forward
-looking statements, which as such are not historical facts, but are based upon v
arious assumptions, many of which are based, in turn, upon further assumptions. T
hese assumptions are inherently subject to significant known and unknown risks, u
ncertainties and other important factors. Such risks, uncertainties, contingencie
s and other important factors could cause actual events to differ materially from
the expectations expressed or implied in this announcement by such forward
-looking statements
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.